Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (796)	4/2/1998 12:53:00 AM
From: StockDoc	Respond to of 887

Dear Dr. Castro, DepoMorphine is an interesting concept. Did they achieve 0-order pharmacokinetics in Phase I? How much morphine is delivered from the device per hour? Is the protocol available on an FDA web site? Did the study start indeed? What's the fundamental difference between this drug and Duragesic? Unsafe drugs can't make it into postop. Duragesic DID NOT get FDA approval for postop use due to poor safety (side effect in 1 in 30 pt). Postop epidural mophine infusion works (0-order) at doses ranging between 100 to 2000 ug/hour, depending on age, gender and pain. It was tricky to titrate my patients to well being without driving them into hypoventillation. How do you think a fixed dose none-0 order sustained-release delivery system could work safely? What can you do in case of accidental overdose in a patient with excruciating pain? I'd appreciate your opinion. StockDoc